Journal article
Kava for the treatment of generalised anxiety disorder (K-GAD): Study protocol for a randomised controlled trial
KM Savage, CK Stough, GJ Byrne, A Scholey, C Bousman, J Murphy, P Macdonald, C Suo, M Hughes, S Thomas, R Teschke, C Xing, J Sarris
Trials | Published : 2015
Abstract
Background: Generalised anxiety disorder (GAD) is a chronic and pervasive condition that generates high levels of psychological stress, and it is difficult to treat in the long term. Current pharmacotherapeutic options for GAD are in some cases only modestly effective, and may elicit undesirable side effects. Through targeted actions on the gamma-aminobutyric acid (GABA) pathway, the South Pacific medicinal plant kava (Piper methysticum) is a non-addictive, non-hypnotic anxiolytic with the potential to treat GAD. The evidence for the efficacy of kava for treating anxiety has been affirmed through clinical trials and meta-analyses. Recent research has also served to lessen safety concerns reg..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
This grant is funded by a National Health and Medical Research Council project grant (APP1063383) and is co-sponsored by MediHerb (Integria Healthcare (Australia) Pty. Ltd). Dr Jerome Sarris is supported by a CR Roper Fellowship. Chad Bousman is supported by a Ronald Phillip Griffith Fellowship. Karen Savage is supported by an APA national scholarship and by an NHMRC grant bursary (APP1063383).